ID | 111271 |
Title Alternative | 浸潤性子宮頸癌における血管内皮増殖因子の発現と微小血管密度の重要性について
|
Author |
Furumoto, Hiroyuki
The University of Tokushima|Tokushima Red Cross Hospital
KAKEN Search Researchers
Yoshida, Kanako
The University of Tokushima
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Nishimura, Masato
The University of Tokushima
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Irahara, Minoru
The University of Tokushima
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
|
Keywords | cervical cancer
vascular endothelial growth factor
microvessel density
bevacizumab
angiogenesis
|
Content Type |
Thesis or Dissertation
|
Description | To determine whether vascular endothelial growth factor (VEGF) expression and microvessel density are predictive of prognosis in cases of invasive cervical cancer, correlations among VEGF expression, microvessel density, and clinicopathological parameters were identified. VEGF expression was evaluated in 50 cervical cancer samples by immunohistochemical staining. Microvessel density was assessed by immunostaining for CD31-positive endothelial cells in the most vascularized areas of tumors. VEGF expression and microvessel density were significantly higher in adenocarcinomas than in squamous cell carcinomas. However, in cases of adenocarcinoma, no significant correlations were found among VEGF expression, microvessel density, and clinicopathological parameters. In contrast, for squamous cell carcinomas, microvessel density was significantly higher in cases at an advanced stage and in those with several other poor prognostic factors. The finding that cervical adenocarcinomas exhibited greater VEGF expression and microvessel density than squamous cell carcinomas may explain the poorer prognosis of adenocarcinoma compared with squamous cell carcinoma. Moreover, microvessel density in squamous cell carcinomas was significantly correlated with poor prognostic factors. Therefore, there is possibility that bevacizumab, a humanized monoclonal antibody against VEGF-A, may be useful in the initial treatment targeting angiogenesis for early-stage cervical cancer.
|
Journal Title |
The Journal of Medical Investigation
|
ISSN | 13496867
13431420
|
NCID | AA11166929
AA12022913
|
Publisher | Faculty of Medicine Tokushima University
|
Volume | 62
|
Issue | 3-4
|
Start Page | 154
|
End Page | 160
|
Sort Key | 154
|
Published Date | 2015-08
|
Remark | 内容要旨・審査要旨・論文本文の公開:
内容要旨・審査要旨 : LID201505211003.pdf 論文本文 : LID201505211004.pdf 本論文は,著者Yasuyo Saijoの学位論文として提出され,学位審査・授与の対象となっている。 西條康代の姓「西」の正確な漢字については審査要旨をご参照ください。 |
EDB ID | |
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
ETD
|
MEXT report number | 甲第2800号
|
Diploma Number | 甲医第1242号
|
Granted Date | 2015-03-19
|
Degree Name |
Doctor of Medical Science
|
Grantor |
Tokushima University
|
departments |
University Hospital
Medical Sciences
|